Get the Stockscreener App
0.972
1.82%
-0.018
Renovorx Inc stock is traded at $0.972, with a volume of 34,478.
It is down -1.82% in the last 24 hours and down -2.80% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.99
Open:
$0.98
24h Volume:
34,478
Relative Volume:
0.27
Market Cap:
$34.72M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.7053
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
+2.32%
1M Performance:
-2.80%
6M Performance:
-0.82%
1Y Performance:
-21.80%
1-Day Range:
$0.97
$1.04
1-Week Range:
$0.94
$1.04
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.972 | 34.72M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx Reports Initial Revenue and Clinical Trial Progress - MSN
RenovoRx CMO Makes Bold Stock Purchase! - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock By Investing.com - Investing.com Canada
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock By Investing.com - Investing.com South Africa
RenovoRx ramps up production of FDA-cleared RenovoCath By Investing.com - Investing.com India
New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment | Newswise - Newswise
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock - Investing.com Australia
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock By Investing.com - Investing.com Canada
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - BioSpace
RenovoRx ramps up production of FDA-cleared RenovoCath - Investing.com
Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community - marketscreener.com
Medical Device Maker RenovoRx Eyes $400M Market With Surging RenovoCath Demand - Stock Titan
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock By Investing.com - Investing.com India
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock - Investing.com
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock By Investing.com - Investing.com India
Top Executives Make Bold Moves with RenovoRx Stock Purchases! - TipRanks
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com - Investing.com Canada
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock - Investing.com Australia
RenovoRx Executives Increase Their Holdings - TradingView
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock - Investing.com
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock - Investing.com
Renovorx director Marton Laurence buys $10,218 in common stock By Investing.com - Investing.com UK
RenovoRx CMO Makes a Bold Move with Major Stock Purchase - TipRanks
RenovoRx Executives Increase Stake in Company - TradingView
Renovorx director Marton Laurence buys $10,218 in common stock - Investing.com
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares - Investing.com Australia
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock - Investing.com
RenovoRx stock hits 52-week low at $0.77 amid market challenges - Investing.com Australia
RenovoRx stock hits 52-week low at $0.77 amid market challenges By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World
H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on RenovoRx stock - Investing.com Australia
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th - Business Wire
RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating - TipRanks
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):